Clinical Application of Non-invasive PGT-A
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04856696 |
Recruitment Status : Unknown
Verified March 2022 by Li-Te Lin, Kaohsiung Veterans General Hospital..
Recruitment status was: Recruiting
First Posted : April 23, 2021
Last Update Posted : March 9, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Genetic Testing | Diagnostic Test: PGT-A Diagnostic Test: non-invasive PGT-A | Not Applicable |
Background Chromosome abnormality is a leading cause of implantation failure and miscarriage. Chromosome abnormality increases with age, resulting in reduced pregnancy rate. Nowadays, preimplantation genetic testing for aneuploidies (PGT-A) could be used for detection of aneuploidy. However, PGT-A needs embryo biopsy which is invasive and may cause embryo damage. It was found that cell free DNA could be isolated from culture media. The cell free DNA from culture media also could be used to detect embryo ploidy, called non-invasive PGT-A.
Objective The study aims to investigate the difference of in vitro fertilization (IVF) outcomes among non-invasive PGT-A, PGT-A and combined non-invasive PGT-A and PGT-A. Another aim of this study is to check the concordance rate between non-invasive PGT-A and PGT-A.
Methods The prospective cohort study will be performed at the reproductive medical center of Kaohsiung Veterans General Hospital, in Kaohsiung, Taiwan. Participants who plan to receive an IVF cycle and preimplantation genetic testing for aneuploidies will be enrolled in this study. The investigators will divide the participants into 3 groups: (1) combined non-invasive PGT-A and PGT-A; (2) PGT-A; (3) non-invasive PGT-A. Basal characteristics, infertility history, ovarian reserve and embryo development of the three groups will be recorded. The samples will be detected ploidy by using next generation sequencing (NGS). Then, the investigators will choose embryo to transfer according to the embryo ploidy and follow the pregnancy outcomes after embryo transfer.
Outcome
- Concordance rate between non-invasive PGT-A and PGT-A
- The relationship between morphological grade and ploidy of non-invasive PGT-A
- IVF outcomes among non-invasive PGT-A, PGT-A and combined non-invasive PGT-A and PGT-A
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | Clinical Application of Non-invasive Preimplantation Genetic Testing for Aneuploidies |
Actual Study Start Date : | March 24, 2021 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | June 30, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: combined non-invasive PGT-A & PGT-A
Infertility women who underwent both non-invasive PGT-A and PGT-A
|
Diagnostic Test: PGT-A
trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform Diagnostic Test: non-invasive PGT-A cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform |
Experimental: non-invasive PGT-A
Infertility women who underwent non-invasive PGT-A only
|
Diagnostic Test: non-invasive PGT-A
cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform |
Active Comparator: PGT-A
Infertility women who underwent PGT-A only
|
Diagnostic Test: PGT-A
trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform |
- Ongoing pregnancy rate [ Time Frame: through study completion, an average of 1.5 year ]continuous presence of a fetal heartbeat over 12 weeks of a pregnancy
- Clinical pregnancy rate [ Time Frame: through study completion, an average of 1.5 year ]the presence of a fetal heartbeat at 6-7 weeks of a pregnancy
- Miscarriage rate [ Time Frame: through study completion, an average of 1.5 year ]pregnancy loss before 24 weeks of gestation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 44 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Infertile women who undergo IVF with PGT
- BMI:18~30 kg/m2
Exclusion Criteria:
- Primary ovarian insufficiency
- Congenital uterine anomaly
- Severe male infertility (azoospermia)
- One of the couples with chromosome abnormality
- Malignancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04856696
Contact: Li-Te Lin | +88673464027 | litelin1982@gmail.com |
Taiwan | |
Kaohsiung Veterans General Hospital | Recruiting |
Kaohsiung, Taiwan, 81362 | |
Contact: Kuan-Hao Tsui, PhD +886-7-3422121 ext 4014 khtsui60@gmail.com | |
Principal Investigator: Li-Te Lin, PhD | |
Sub-Investigator: Salvatore Giovanni Vitale |
Study Director: | Kuan-Hao Tsui | Kaohsiung Veterans General Hospital. |
Responsible Party: | Li-Te Lin, Attending doctor, Department of Obstetrics and Gynecology, Principal Investigator, Assistant professor, Kaohsiung Veterans General Hospital. |
ClinicalTrials.gov Identifier: | NCT04856696 |
Other Study ID Numbers: |
KSVGH20-CT12-16 |
First Posted: | April 23, 2021 Key Record Dates |
Last Update Posted: | March 9, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
PGT PGT-A non-invasive PGT-A |
embryo biopsy spent media cell free DNA |